PT-141 (Bremelanotide) Research Profile

Research Use

PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist acting centrally in the brain's hypothalamus to induce sexual arousal. Unlike PDE5 inhibitors, it targets the central nervous system, making it effective even in cases of psychogenic sexual dysfunction.

PT-141 (Bremelanotide) Quick Technical Specifications

Category
Melanocortin Receptor
Elimination Half-Life
approx. 2.7 hours
Storage Protocol
Refrigerated (2°C-8°C)
Status
Research Use
OE
Written by OnePeptideShip Editorial Team
Reviewed by Dr. Aris Thorne, MD, Board Certified Endocrinology Advisor
Updated September 2026

Mechanism of Action & Biochemical Context

PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist acting centrally in the brain's hypothalamus to induce sexual arousal. Unlike PDE5 inhibitors, it targets the central nervous system, making it effective even in cases of psychogenic sexual dysfunction.

Storage, Reconstitution & Stability Guidelines

Prior to reconstitution, lyophilized PT-141 (Bremelanotide) powder should be stored away from light between 2°C and 8°C for short-term access, or -20°C for long-term preservation. Once reconstituted with Bacteriostatic Water (0.9% benzyl alcohol preservative), maintain strict refrigeration between 2°C and 8°C. Do not freeze liquid solution.

Cited Scientific References

  1. Clayton AH, et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women. Obstet Gynecol. 2019.

Calculate PT-141 (Bremelanotide) Syringe Units

Input your vial mg and BAC water mL to calculate exact U-100 draw units.

Open PT-141 (Bremelanotide) Calculator →

Frequently Asked Questions

From a 10mg vial mixed with 2mL of Bacteriostatic Water (concentration: 5mg/mL), a 1.0mg dose requires drawing 0.2mL = 20 units on a U-100 syringe. For the maximum 1.75mg dose, you would draw 0.35mL = 35 units.

Due to the high risk of severe nausea (especially in subjects who have never used it before), most research protocols begin with 0.5mg (10 units using standard 2mL reconstitution) as a "tolerance test" dose. After assessing nausea tolerance, doses are escalated to 1.0mg, then 1.5mg, and finally the maximum 1.75mg in subsequent research sessions.

Inject 4 to 6 hours before intended activity. This is one of the most important timing factors - the onset is dramatically different from PDE5 inhibitors like Viagra (30 minutes). The arousal effects typically peak between 4-8 hours post-injection and can persist for 24-72 hours. Many researchers inject the night before.

Yes. PT-141 (Bremelanotide) received FDA approval specifically for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) under the brand name Vyleesi. Clinical trials demonstrated significant improvements in sexual desire scores and reductions in distress related to low libido. The mechanism (central MC4R activation) works identically in both sexes.

PT-141 nausea is centrally-mediated (it originates in the brain, not the stomach). The most effective countermeasure is pre-medicating with an anti-nausea drug 30-60 minutes before injection. Researchers commonly use: Zofran (ondansetron, the most effective), Phenergan (promethazine), or even a standard antihistamine like Benadryl/Dramamine. Injecting before bed so you sleep through the first 2-3 hours is also highly effective.

Some researchers stack PT-141 (which acts centrally on desire/arousal) with low-dose daily Cialis (which acts peripherally on blood flow). The combination can be highly synergistic. However, both compounds lower blood pressure, and combining them can cause significant hypotension (dizziness, fainting). Always start with very low doses of both if stacking.

PT-141 is derived from Melanotan II, which was originally a tanning peptide. However, PT-141 lacks the cyclic backbone that gives Melanotan II its strong melanogenesis (tanning) activity. PT-141 has minimal tanning effect and is used exclusively for sexual dysfunction. If tanning is the goal, Melanotan II or MT-1 are the correct compounds.